Rarecells Molecular Biomarkers for Early Detection of Lung Cancer (BioMolCTC)

Rarecells Diagnostics SAS

Status: Enrolling

Conditions: Lung Cancer; Pulmonary Neoplasm

Treatments: Diagnostic Test: CTC-DNA

Study type: Observational

Funder types: Industry

Identifiers

NCT06546007

BIOMOLCTC-24-01

Details and patient eligibility

About

Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.

This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.

Full description

Researching for tumor biomarkers in the blood, circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA) can non-invasively detect signs of cancer without risk to the patient. These are ideal and risk-free methods for monitoring patients and early detection of lung cancer.

This study aims to assess the sensitivity of molecular analyses performed on circulating tumor DNA in the blood and on DNA from circulating tumor cells, isolated using the highly sensitive ISET® method. The purpose is to assess two circulating molecular biomarkers in the field of liquid biopsy in patients with lung cancer: Rarecells ISET® CTC-DNA and ctDNA.

Subjects eligible for inclusion in the study are individuals diagnosed with operable lung cancer who will undergo biopsy or surgical resection of the tumor. Upon enrolment in the trial, participants will undergo an assessment including low-dose CT scan, isolation of CTCs by the ISET® method, and separation of plasma for analysis of ctDNA.

Enrollment: 50 estimated patients

Sex: All

Ages: 35 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female aged between 35 and 85 years
2. Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
3. Patient capable of giving free, informed, and express consent

The assessment of successful elected surgery implies, but is not limited to, the following:

• Exclusion of detectable extra thoracic and distant metastases
• Determination of the presence or absence of superior mediastinal lymph node metastases
• Definition of the histologic or cell type, whenever possible
• Evaluation of operative risk

Exclusion criteria

1. Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
2. Patient treated with neoadjuvant treatment
3. Pregnant women
4. Patient presenting psychiatric or neurological disorders preventing them from understanding the research

Trial design

50 participants in 1 patient group

Patient with early lung cancer

Description:

Patients with a diagnosis of lung cancer, planned for lung resection with curative intent.

Treatment:

Diagnostic Test: CTC-DNA